BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ryan E, Seehra G, Sharma P, Sidransky E. GBA1-associated parkinsonism: new insights and therapeutic opportunities. Curr Opin Neurol 2019;32:589-96. [PMID: 31188151 DOI: 10.1097/WCO.0000000000000715] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Ruz C, Alcantud JL, Vives F, Arrebola F, Hardy J, Lewis PA, Manzoni C, Duran R. Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line. IJMS 2022;23:6935. [DOI: 10.3390/ijms23136935] [Reference Citation Analysis]
2 Vrijsen S, Vrancx C, Del Vecchio M, Swinnen JV, Agostinis P, Winderickx J, Vangheluwe P, Annaert W. Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites. Front Neurosci 2022;16:900338. [DOI: 10.3389/fnins.2022.900338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Galvagnion C, Marlet FR, Cerri S, Schapira AHV, Blandini F, Di Monte DA. Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation. Brain 2022:awab371. [PMID: 35362022 DOI: 10.1093/brain/awab371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
4 Beger AW, Dudzik B, Woltjer RL, Wood PL. Human Brain Lipidomics: Pilot Analysis of the Basal Ganglia Sphingolipidome in Parkinson’s Disease and Lewy Body Disease. Metabolites 2022;12:187. [DOI: 10.3390/metabo12020187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Grosso Jasutkar H, Oh SE, Mouradian MM. Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease. Pharmacol Rev 2022;74:207-37. [PMID: 35017177 DOI: 10.1124/pharmrev.120.000133] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
6 Mehendale N, Mallik R, Kamat SS. Mapping Sphingolipid Metabolism Pathways during Phagosomal Maturation. ACS Chem Biol 2021;16:2757-65. [PMID: 34647453 DOI: 10.1021/acschembio.1c00393] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 He JM, Wu ZB, Cai NQ, Lin Y. Levodopa-Induced Ocular Dyskinesia in an Early-Onset Parkinson Disease Patient With GBA Mutation. Clin Neuropharmacol 2021;44:201-4. [PMID: 34654015 DOI: 10.1097/WNF.0000000000000484] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Caminiti SP, Carli G, Avenali M, Blandini F, Perani D. Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations. Mov Disord 2021. [PMID: 34596920 DOI: 10.1002/mds.28818] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
9 Pergel E, Veres I, Csigi GI, Czirják G. Translocation of TMEM175 Lysosomal Potassium Channel to the Plasma Membrane by Dynasore Compounds. Int J Mol Sci 2021;22:10515. [PMID: 34638858 DOI: 10.3390/ijms221910515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Behl T, Madaan P, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harrasi A, Chigurupati S, Alrashdi I, Bungau SG. Elucidating the Neuroprotective Role of PPARs in Parkinson's Disease: A Neoteric and Prospective Target. Int J Mol Sci 2021;22:10161. [PMID: 34576325 DOI: 10.3390/ijms221810161] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
11 Logan T, Simon MJ, Rana A, Cherf GM, Srivastava A, Davis SS, Low RLY, Chiu CL, Fang M, Huang F, Bhalla A, Llapashtica C, Prorok R, Pizzo ME, Calvert MEK, Sun EW, Hsiao-Nakamoto J, Rajendra Y, Lexa KW, Srivastava DB, van Lengerich B, Wang J, Robles-Colmenares Y, Kim DJ, Duque J, Lenser M, Earr TK, Nguyen H, Chau R, Tsogtbaatar B, Ravi R, Skuja LL, Solanoy H, Rosen HJ, Boeve BF, Boxer AL, Heuer HW, Dennis MS, Kariolis MS, Monroe KM, Przybyla L, Sanchez PE, Meisner R, Diaz D, Henne KR, Watts RJ, Henry AG, Gunasekaran K, Astarita G, Suh JH, Lewcock JW, DeVos SL, Di Paolo G. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell 2021;184:4651-4668.e25. [PMID: 34450028 DOI: 10.1016/j.cell.2021.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zampieri S, Cattarossi S, Pavan E, Barbato A, Fiumara A, Peruzzo P, Scarpa M, Ciana G, Dardis A. Accurate Molecular Diagnosis of Gaucher Disease Using Clinical Exome Sequencing as a First-Tier Test. Int J Mol Sci 2021;22:5538. [PMID: 34073924 DOI: 10.3390/ijms22115538] [Reference Citation Analysis]
13 Coccia E, Ahfeldt T. Towards physiologically relevant human pluripotent stem cell (hPSC) models of Parkinson's disease. Stem Cell Res Ther 2021;12:253. [PMID: 33926571 DOI: 10.1186/s13287-021-02326-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Panicker N, Ge P, Dawson VL, Dawson TM. The cell biology of Parkinson's disease. J Cell Biol 2021;220:e202012095. [PMID: 33749710 DOI: 10.1083/jcb.202012095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
15 Wang XL, Feng ST, Wang YT, Yuan YH, Li ZP, Chen NH, Wang ZZ, Zhang Y. Mitophagy, a Form of Selective Autophagy, Plays an Essential Role in Mitochondrial Dynamics of Parkinson's Disease. Cell Mol Neurobiol 2021. [PMID: 33528716 DOI: 10.1007/s10571-021-01039-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Liu X, Le W. Profiling Non-motor Symptoms in Monogenic Parkinson's Disease. Front Aging Neurosci 2020;12:591183. [PMID: 33192488 DOI: 10.3389/fnagi.2020.591183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
17 Gracia P, Camino JD, Volpicelli-Daley L, Cremades N. Multiplicity of α-Synuclein Aggregated Species and Their Possible Roles in Disease. Int J Mol Sci 2020;21:E8043. [PMID: 33126694 DOI: 10.3390/ijms21218043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
18 Mahungu AC, Anderson DG, Rossouw AC, van Coller R, Carr JA, Ross OA, Bardien S. Screening of the glucocerebrosidase (GBA) gene in South Africans of African ancestry with Parkinson's disease. Neurobiol Aging 2020;88:156.e11-4. [PMID: 32035846 DOI: 10.1016/j.neurobiolaging.2019.12.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Bohnen NI, Albin RL. Increased striatal dopamine in carriers of GBA mutations: compensation or epiphenomenon? Lancet Neurol 2020;19:27-9. [PMID: 31678033 DOI: 10.1016/S1474-4422(19)30355-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]